Robert J. Gould, Director at Fulcrum Therapeutics, Inc. (FULC), sold 30,000 shares at $10.72 ($322K) on 2026-02-02, disclosed to the SEC on 2026-02-04.
Open-market sale of $322k FULC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.72 | 15,000 | $161K | 50.0% |
| 2 | $10.72 | 15,000 | $161K | 50.0% |
| Total | $10.72 avg | 30,000 | $322K | 100% |
| Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |
| FULC | SELL | 2022-06-08 | $1.2M | — | Filing → |